Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
Source: The Hindu
Category: Technology
Region: General
Published: July 04, 2026 at 08:37
📝 Summary
The trial will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said